Author: Xiaoli Zhao
Formerly a physiologist and professor in academia, Xiaoli is a program director in the Division of Pharmacology, Physiology, and Biological Chemistry. She administers research grant programs in sepsis and septic shock, injury and critical illness, inflammation and innate immunity, as well as institutional postdoctoral training grants in injury and critical care.
Posts by Xiaoli Zhao
The ARDS, Pneumonia, and Sepsis (APS) Consortium is funded through a collaboration between the National Heart, Lung, and Blood Institute and NIGMS. This large observational study will collect longitudinal data and biospecimens from approximately 4,000 adults hospitalized with acute respiratory distress syndrome (ARDS), pneumonia, or sepsis at over 20 hospitals in the United States. The scientific goal is to conduct analyses to gain greater understanding of the biological mechanisms underlying APS and, in particular, to link to well-defined clinical phenotypes.
Continue reading “APS Consortium Study Materials Publicly Available”
We’ve issued a new notice: NIGMS Support to Utilize Data and Biospecimens Generated by the ARDS, Pneumonia, and Sepsis (APS) Phenotyping Consortium (NOT-GM-24-018). The purpose is to inform investigators that we’ll support studies that fall within the NIGMS mission and utilize biospecimens or data generated from the APS Consortium.
Continue reading “Notice: NIGMS Support to Utilize Data and Biospecimens Generated by the ARDS, Pneumonia, and Sepsis Phenotyping Consortium”
We want the research community to know about two funding opportunity announcements (FOAs) that NIGMS has joined as part of an NHLBI initiative to support the formation of a multisite study, the Acute Respiratory Distress Syndrome (ARDS), Pneumonia, and Sepsis Phenotyping (APS) Consortium. The study seeks to better define the heterogeneity underlying critical illness syndromes and to identify the mechanisms of illness development and recovery, as well as relationships and overlap between these syndromes. The FOAs are:
Continue reading “Funding Opportunities: The ARDS, Pneumonia, and Sepsis Phenotyping Consortium”
We’ve issued a new funding opportunity announcement (FOA): Exploring the Scientific Value of Existing or New Sepsis Human Biospecimen Collections (R21/R33 – Clinical Trial Not Allowed) (PAR-21-077). This FOA aims to promote the optimal use, testing, and sharing of patient-derived materials. It stems from recommendations of the NAGMSC working group on sepsis and input from the scientific community for strategies to rebalance NIGMS’ investment in sepsis research.
Continue reading “Funding Opportunity: R21/R33 to Test Existing or New Biospecimens from Sepsis Patients”
